CHF 100’000 for ASPIVIX

FIT | 02 October 2018

ASPIVIX is the newest winner of a FIT seed loan of CHF 100’000. The Lausanne based medtech startup develops a novel medical device for gynaecologists, which eases treatments and reduces pain as well as eventual trauma during interventions.

Every year in the world, 65 million women go through gynaecological treatments or procedures requiring access to the uterus. This is the case for the insertion of intra-uterine contraceptive devices (IUCD) for instance. To perform such interventions today, gynaecologists use standard Tenaculum forceps, which in most cases cause pain or trauma for the patients.

With decades of experience in the Medical field and the willingness to make gynaecological interventions less painful for millions of women in the world, the founding team of ASPIVIX (two co-founders have a background in the Medical Device Industry, one is an obstetrician-gynecologist Medical Doctor) decided to develop a novel and painless instrument. The result is the next generation of single-use forceps featuring a patented gentle vacuum suction pad. The device reduces pain and eliminates lesions as well as cross-contamination.

ASPIVIX’s product is the ideal instrument to break barriers to the adoption of intra-uterine contraceptive devices, the most effective contraceptive solution in the world today. The FIT seed loan of CHF 100’000 will now help the startup to conduct clinical studies and industrialize the product.

Download the image of ASPIVIX product

Aspivix in vidéo

Contact: Mathieu Horras, CEO |